150 completed, 16 terminated, 8 unknown, 6 recruiting. 84 Phase 3, 62 Phase 2, 23 Phase 4, 15 Phase 1, 12 Not applicable.
Follow Darbepoetin alfa: new trials by email Literature Review of Darbepoetin alfa trials Research Report on Darbepoetin alfa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Therapy of Romiplostim and Erythropoiesis-stimulating Agents Romiplostim, darbepoetin alfa, Methoxy Polyethylene Glycol-Epoetin Beta - Anemia Associated With Chronic Kidney Disease | Phase 2 | Recruiting | Chinese University of Hong Kong | 12 | 2026-08-11 | 2026-10-02 |
| Effects of Vadadustat on Anemia, Quality of Life, and Inflammation in Dialysis Patients Vadadustat - Renal Anemia | Phase 4 | Not yet recruiting | Mackay Memorial Hospital | 40 | 2026-04-15 | 2026-04-23 |
| Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes Testosterone Enanthate, Testosterone Cypionate, Testosterone Propionate - Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes | Not applicable | Enrolling by invitation | Enhanced Emirates Limited | 60 | 2026-03-12 | 2026-05-06 |
| A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) Daprodustat, Darbepoetin alfa - Anaemia | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 100 | 2025-12-31 | 2025-12-23 |
| Darbepoetin in Patients Candidates for Liver Transplant. (EPO-LT Trial) Darbepoetin (DP) - Liver Transplant; Complications | Phase 3 | Recruiting | Fundacion Clinic per a la Recerca Biomédica | 140 | 2025-11-25 | 2025-12-18 |
| Project CARE: CAncer Risk Evaluation Relational Agent ( RA) Alex - Primary Care | Not applicable | Recruiting | Anita Y. Kinney, PhD, RN | 210 | 2025-11-19 | 2025-11-25 |
| National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated Cirrhosis Gcsf, Darbepoetin, Standard Medical Treatment - Decompensated Cirrhosis | Not applicable | Not yet recruiting | Institute of Liver and Biliary Sciences, India | 110 | 2025-09-01 | 2025-08-20 |
| Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis. Darbepoetin, G-CSF, Lactulose - Decompensated Liver Cirrhosis | Not applicable | Recruiting | Institute of Liver and Biliary Sciences, India | 60 | 2025-06-04 | 2026-05-22 |
| The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy Roxadustat, Darbepoietin Alfa - Diabetes Complications, Diabetes; Nephropathy (Manifestation) | Phase 2 | Not yet recruiting | Region Stockholm | 30 | 2025-06-01 | 2024-11-19 |
| Vafseo Outcomes In-Center Experience Vadadustat, Erythropoiesis Stimulating Agent - Anemia of Chronic Kidney Disease | Phase 3 | Active not recruiting | USRC Kidney Research | 2200 | 2024-11-20 | 2026-03-10 |
| A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis Efepoetin Alfa, Darbepoetin Alfa - Anemia of Chronic Kidney Disease | Phase 3 | Recruiting | Genexine, Inc. | 429 | 2024-01-25 | 2026-05-22 |
| Choices About Genetic Testing And Learning Your Risk With Smart Technology Relational Agent (RA), Enhanced Usual Care (EUC) - Ovarian Cancer, Fallopian Tube Cancer | Not applicable | Completed | Rutgers, The State University of New Jersey | 50 | 2023-09-26 | 2026-03-06 |
| Pharmacokinetics Comparison Study of JT1801 and NESP® After Single Dose Administration in Chinese Health Male Volunteers JT1801 60ug, NESP 60ug - Renal Anemia | Phase 4 | Completed | Yi Fang | 74 | 2023-05-15 | 2023-11-22 |
| A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis AND017 capsules TIW, AND017 capsules QW, epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars - Renal Anemia | Phase 2 | Completed | Kind Pharmaceuticals LLC | 175 | 2023-05-03 | 2024-06-28 |
| High Dose IV Iron Plus ESA in Chemotherapy-induced Anemia Ferric Derisomaltose Injection, Darbepoetin Alfa Injection - Anemia | Phase 3 | Unknown | Hallym University Medical Center | 312 | 2023-03-01 | 2023-03-15 |
| Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants Darbepoetin Alfa, Low Molecular Weight Iron Dextran, Ferumoxytol injection - Prematurity, Iron-deficiency | Phase 2 | Recruiting | University of Washington | 120 | 2022-11-27 | 2026-05-26 |
| Darbepoetin in Neonatal Encephalopathy Trial Darbepoetin Alfa - Neonatal Encephalopathy | Phase 2 | Unknown | Imperial College London | 150 | 2021-05-28 | 2024-03-19 |
| Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA Canakinumab Injection, Darbepoetin Alfa - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 13 | 2021-03-30 | 2025-10-31 |
| Mechanisms of EPO-induced Hypertension Darbepoetin - Chronic Kidney Disease, Blood Pressure | Phase 2 | Terminated | VA Office of Research and Development | 27 | 2021-01-04 | 2025-12-15 |
| Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs) Vadadustat, Darbepoetin alfa - Anemia | Phase 3 | Completed | Akebia Therapeutics | 319 | 2020-05-27 | 2025-05-22 |
Showing 20 of 191. Sign in to see all of them.
Anemia (117) · Renal Insufficiency, Chronic (47) · Neoplasms (19) · Kidney Diseases (16) · Kidney Failure, Chronic (12) · Myelodysplastic Syndromes (11) · Breast Neoplasms (7) · Heart Failure (6) · Lymphoma, Large B-Cell, Diffuse (6) · Renal Insufficiency (6) · Lymphoma (5) · Diabetes Mellitus (4) · Leukemia (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lung Neoplasms (4)
Amgen (62) · Hoffmann-La Roche (12) · Akebia Therapeutics (7) · Bayer (5) · Biocad (4) · Chong Kun Dang Pharmaceutical (4) · GlaxoSmithKline (4) · Kyowa Kirin Co., Ltd. (3) · M.D. Anderson Cancer Center (3) · Affymax (2) · Astellas Pharma Europe B.V. (2) · Astellas Pharma Inc (2) · Chinese University of Hong Kong (2) · Genexine, Inc. (2) · Institute of Liver and Biliary Sciences, India (2)
United States (47) · France (25) · Germany (24) · Italy (24) · Spain (24) · United Kingdom (24) · Poland (22) · South Korea (22) · Australia (19) · Belgium (18) · Russia (18) · Japan (16) · Czechia (15) · Hungary (15) · Canada (14)
Anita Y Kinney, PhD, RN (2) · Gautam Borthakur, MBBS (2) · Kyung Sang Yu, Ph.D (2) · Nagahiro Saijo, MD (2) · Roman Ivanov, PhD (2) · Vice President, Clinical Development (2) · Adam Rosenberg, MD (1)
PMID 36005278, PMID 36791280, PMID 40359056, PMID 18328118, PMID 16710026, PMID 18227526, PMID 23343061, PMID 23343062, PMID 31203242, PMID 33913637, PMID 33913638, PMID 37095342, PMID 37096396, PMID 38530490, PMID 12481149, PMID 12957457, PMID 14770445, PMID 15352656, PMID 15909591, PMID 15911237, PMID 16177289, PMID 16381629, PMID 16411031, PMID 16478746, PMID 16614237, PMID 16724235, PMID 17116009, PMID 17289537, PMID 17295668, PMID 17306703, PMID 17329707, PMID 17522247, PMID 17559735, PMID 17602062, PMID 17694552, PMID 17962619, PMID 18195176, PMID 18375890, PMID 18467726, PMID 18540943, PMID 18565240, PMID 18586762, PMID 18586927, PMID 18632499, PMID 18642348, PMID 18675764, PMID 18827613, PMID 19501439, PMID 19601709, PMID 19728887
2016 (4), 2005 (2), 2009 (2), 2015 (2), P30CA015083 (2), 2017 (1), 2019 (1), R01HD107003 (1), U10CA031946 (1)